Frontier IP looks to the future with confidence
Strong interim results, with several portfolio companies now on the cusp of important inflection points reflecting the significant commercial, technical and industrial progress they made during the first half and beyond.
The Vaccine Group to collaborate with The Pirbright Institute and ECO Animal Health Group
Portfolio company TVG to develop prototype vaccines to tackle porcine reproductive and respiratory syndrome virus (PRRSV) in 18-month project with The Pirbright Institute and ECO Animal Health.
The Vaccine Group makes significant progress with COVID-19 animal vaccines
Portfolio company The Vaccine Group has made significant progress in developing animal vaccines based on its novel technology to tackle COVID-19.
The Vaccine Group starts work on COVID-19 animal vaccine
Move follows significant progress across several projects
The Vaccine Group starts work on COVID-19 animal vaccine, makes strong progress with technology
The Vaccine Group is today announcing it has made significant progress towards developing its novel vaccine platform technology